Skip to main content
. Author manuscript; available in PMC: 2013 Mar 12.
Published in final edited form as: Eur J Immunol. 2011 Oct 26;41(12):10.1002/eji.201141383. doi: 10.1002/eji.201141383

Figure 3. Effect of DCs transfected with soluble GITR-L fusion protein mRNA and anti-CTLA-4 mAb mRNA on melanoma antigen-specific CTL responses.

Figure 3

DCs transfected with TAA mRNA (combination of MART-1, gp100, MAGE-3 and tyrosinase mRNAs) or GFP mRNA, and either control (actin) mRNA, GITR-L mRNA, humanized anti-CTLA-4 mAb (α-CTLA-4) mRNA, or GITR-L mRNA+α-CTLA-4 mRNA were used to stimulate autologous T cells weekly 2 times followed by a CTL assay. Induction of TAA-specific CTLs was measured using mRNA-transfected DCs and tumor targets. This experiment was performed three times, using cells from different donors, each with similar results. Data show mean +/−SD?. (A) DC targets: Targets were autologous DCs transfected with mRNA encoding TAA’s MART-1, gp100, MAGE-3 and tyrosinase (DC-TAA) or transfected with GFP (DC-GFP). (B) Tumor cell targets: Because the donor for these experiments was HLA-A2+, CTL activity was assessed against the HLA-A2+ melanoma cell lines DM6 and A375, and the HLA-A2+ tumor cell line 293 that does not express TAA’s MART-1, gp100, MAGE-3 or tyrosinase.